---
title: "Lysergide (DT120) in Generalized anxiety disorder: Mechanism of action"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Mechanism of action. Topics: Classic serotonergic psychedelic and partial agonist at serotonin-2A receptors, Registry description of the investigational product, Mechanism in anxiety not established, Dependence of the acute response on serotonin-2A receptors: ketanserin studies, and 1 further topic. 5 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Classic serotonergic psychedelic and partial agonist at serotonin-2A receptors

> “DT120 ODT is an ergoline derivative belonging to the group of classic serotonergic psychedelics, which acts as a partial agonist at serotonin-2A (5-HT2A) receptors.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.6.1-2"></a>

### Registry description of the investigational product

> “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-2.1.2.6.1-3"></a>

### Mechanism in anxiety not established

> “Lysergide, or lysergic acid diethylamide (LSD), is a semisynthetic psychedelic drug in the ergoline family.”
> “Although LSD’s precise mechanism of action in the treatment of psychiatric illness is unknown, mechanistic hypotheses implicate its acute psychological effects (mediated by agonism of the 5-HT2A receptor) and its sustained increases in neuroplasticity in a variety of brain regions as potentially responsible.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “The precise mechanism by which lysergide modulates anxiety and depression is still under investigation, but recent neuroimaging studies have provided a plausible explanation for clinical efficacy in these disease areas.”
> “This increase in connectivity between brain regions is correlated with perceptual alterations that are believed to contribute to subsequent and persistent improvements in psychological functioning.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.6.1-4"></a>

### Dependence of the acute response on serotonin-2A receptors: ketanserin studies

> “Administration of the 5-HT 2A antagonist ketanserin before LSD almost fully blocks the acute subjective response to LSD.”
> “These findings are consistent with an interaction between ketanserin and LSD and the view that LSD produces its psychedelic effects only when occupying 5-HT 2A receptors.”

Source: [Becker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9926053/)

> “Ketanserin effectively prevented the response to 200 µg LSD.”
> “The full psychedelic effects of LSD are primarily mediated by serotonin 5-HT 2A receptor activation.”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

<a id="topic-2.1.2.6.1-5"></a>

### Serotonin receptor activity of LSD and its metabolites in vitro

> “LSD and nor-LSD were pharmacologically active at the 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors.”
> “Nor-LSD mainly differed from the parent compound by having a lower affinity to the 5-HT2C receptor.”
> “O-H-LSD displayed substantially weaker affinity and activity at serotonergic receptors in comparison to LSD.”

Source: [Luethi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30981875/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
